Population characteristics
| Characteristics . | Value . |
|---|---|
| n | 51 |
| Recipient demographics | |
| Age (years) | 53 ± 11 |
| Male sex | 28 (55) |
| Time since transplantation (years) | 7.5 (5.2–12.0) |
| Cadaveric donor | 46 (90) |
| Body composition | |
| BMI (kg/m2) | 26.0 (23.8–28.6) |
| Waist circumference (cm) | 101 ± 12 |
| Waist-to-hip ratio | 1.03 (0.92–1.09) |
| Renal function and proteinuria | |
| Creatinine clearance (ml/min) | 65 (57–78) |
| Serum creatinine (μmol/l) | 134 (106–149) |
| Proteinuria (g/24 h) | 0.1 (0.0–0.2) |
| Blood pressure | |
| Systolic blood pressure (mmHg) | 145 ± 15 |
| Diastolic blood pressure (mmHg) | 85 ± 11 |
| Lipids | |
| Total cholesterol (mmol/l) | 5.4 ± 0.9 |
| LDL cholesterol (mmol/l) | 3.3 ± 0.8 |
| HDL cholesterol (mmol/l) | 1.3 (0.9–1.7) |
| Triglycerides (mmol/l) | 1.7 (1.1–2.4) |
| Medication | |
| Antihypertensive | |
| β-Blocker | 6 (12) |
| ACE inhibitor | 20 (40) |
| Angiotensin II antagonist | 4 (7) |
| Calcium antagonist | 19 (38) |
| Diuretics | 22 (44) |
| Lipid-lowering drugs | |
| Statine | 37 (72) |
| Immunosuppresion | |
| Prednisolone dose (mg/day) | 10 (7.5–10) |
| Cyclosporine | 51 (100) |
| Trough-level (μg/l) | 109 (78–143) |
| Azathioprine | 10 (20) |
| Mycophenolate mofetil | 13 (25) |
| Trough level (μg/l) | 1.5 (1.1–3.6) |
| Rapamycine | 1 (2) |
| Characteristics . | Value . |
|---|---|
| n | 51 |
| Recipient demographics | |
| Age (years) | 53 ± 11 |
| Male sex | 28 (55) |
| Time since transplantation (years) | 7.5 (5.2–12.0) |
| Cadaveric donor | 46 (90) |
| Body composition | |
| BMI (kg/m2) | 26.0 (23.8–28.6) |
| Waist circumference (cm) | 101 ± 12 |
| Waist-to-hip ratio | 1.03 (0.92–1.09) |
| Renal function and proteinuria | |
| Creatinine clearance (ml/min) | 65 (57–78) |
| Serum creatinine (μmol/l) | 134 (106–149) |
| Proteinuria (g/24 h) | 0.1 (0.0–0.2) |
| Blood pressure | |
| Systolic blood pressure (mmHg) | 145 ± 15 |
| Diastolic blood pressure (mmHg) | 85 ± 11 |
| Lipids | |
| Total cholesterol (mmol/l) | 5.4 ± 0.9 |
| LDL cholesterol (mmol/l) | 3.3 ± 0.8 |
| HDL cholesterol (mmol/l) | 1.3 (0.9–1.7) |
| Triglycerides (mmol/l) | 1.7 (1.1–2.4) |
| Medication | |
| Antihypertensive | |
| β-Blocker | 6 (12) |
| ACE inhibitor | 20 (40) |
| Angiotensin II antagonist | 4 (7) |
| Calcium antagonist | 19 (38) |
| Diuretics | 22 (44) |
| Lipid-lowering drugs | |
| Statine | 37 (72) |
| Immunosuppresion | |
| Prednisolone dose (mg/day) | 10 (7.5–10) |
| Cyclosporine | 51 (100) |
| Trough-level (μg/l) | 109 (78–143) |
| Azathioprine | 10 (20) |
| Mycophenolate mofetil | 13 (25) |
| Trough level (μg/l) | 1.5 (1.1–3.6) |
| Rapamycine | 1 (2) |
Data are means ± SD, n (%), or median (interquartile range).